Search

Your search keyword '"Dirix, Luc"' showing total 1,337 results
Start Over Author "Dirix, Luc"
1,337 results on '"Dirix, Luc"'

1. Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases

Author

Leduc, Sophia, Nguyen, Ha-Linh, Richard, François, Zels, Gitte, Mahdami, Amena, De Schepper, Maxim, Maetens, Marion, Pabba, Anirudh, Jaekers, Joris, Latacz, Emily, Bohlok, Ali, Vanderheyden, Evy, Van Brussel, Thomas, Boeckx, Bram, Schepers, Rogier, Lambrechts, Diether, Dirix, Luc, Larsimont, Denis, Vankerckhove, Sophie, Lucidi, Valerio, Topal, Baki, Bachir, Imane, Donckier, Vincent, Floris, Giuseppe, Vermeulen, Peter, and Desmedt, Christine

Published
2024
Full Text
View/download PDF

2. Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases

Author

Leduc, Sophia, De Schepper, Maxim, Richard, François, Maetens, Marion, Pabba, Anirudh, Borremans, Kristien, Jaekers, Joris, Latacz, Emily, Zels, Gitte, Bohlok, Ali, Van Baelen, Karen, Nguyen, Ha Linh, Geukens, Tatjana, Dirix, Luc, Larsimont, Denis, Vankerckhove, Sophie, Santos, Eva, Oliveira, Rui Caetano, Dede, Kristòf, Kulka, Janina, Borbala, Székely, Salamon, Ferenc, Madaras, Lilla, Marcell Szasz, A., Lucidi, Valerio, Meyer, Yannick, Topal, Baki, Verhoef, Cornelis, Engstrand, Jennie, Moro, Carlos Fernandez, Gerling, Marco, Bachir, Imane, Biganzoli, Elia, Donckier, Vincent, Floris, Giuseppe, Vermeulen, Peter, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

4. An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver

Author

Fernández Moro, Carlos, Geyer, Natalie, Harrizi, Sara, Hamidi, Yousra, Söderqvist, Sara, Kuznyecov, Danyil, Tidholm Qvist, Evelina, Salmonson Schaad, Media, Hermann, Laura, Lindberg, Amanda, Heuchel, Rainer L., Martín-Bernabé, Alfonso, Dhanjal, Soniya, Navis, Anna C., Villard, Christina, del Valle, Andrea C., Bozóky, Lorand, Sparrelid, Ernesto, Dirix, Luc, Strell, Carina, Östman, Arne, Schmierer, Bernhard, Vermeulen, Peter B., Engstrand, Jennie, Bozóky, Béla, and Gerling, Marco

Published
2023
Full Text
View/download PDF

6. Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.

Author

Bartlett, John MS, Bayani, Jane, Kornaga, Elizabeth, Xu, Keying, Pond, Greg R, Piper, Tammy, Mallon, Elizabeth, Yao, Cindy Q, Boutros, Paul C, Hasenburg, Annette, Dunn, JA, Markopoulos, Christos, Dirix, Luc, Seynaeve, Caroline, van de Velde, Cornelis JH, Stein, Robert C, and Rea, Daniel

Subjects
Cancer, Breast Cancer, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies
Abstract

Multiparametric assays for risk stratification are widely used in the management of both node negative and node positive hormone receptor positive invasive breast cancer. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient level. The TEAM pathology study consists of 3284 postmenopausal ER+ve breast cancers treated with endocrine therapy Using genes comprising the following multi-parametric tests OncotypeDx®, Prosigna™ and MammaPrint® signatures were trained to recapitulate true assay results. Patients were then classified into risk groups and survival assessed. Whilst likelihood χ2 ratios suggested limited value for combining tests, Kaplan-Meier and LogRank tests within risk groups suggested combinations of tests provided statistically significant stratification of potential clinical value. Paradoxically whilst Prosigna-trained results stratified Oncotype-trained subgroups across low and intermediate risk categories, only intermediate risk Prosigna-trained cases were further stratified by Oncotype-trained results. Both Oncotype-trained and Prosigna-trained results further stratified MammaPrint-trained low risk cases, and MammaPrint-trained results also stratified Oncotype-trained low and intermediate risk groups but not Prosigna-trained results. Comparisons between existing multiparametric tests are challenging, and evidence on discordance between tests in risk stratification presents further dilemmas. Detailed analysis of the TEAM pathology study suggests a complex inter-relationship between test results in the same patient cohorts which requires careful evaluation regarding test utility. Further prognostic improvement appears both desirable and achievable.

Published
2021

7. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Author

Magbanua, Mark Jesus M, Hendrix, Laura H, Hyslop, Terry, Barry, William T, Winer, Eric P, Hudis, Clifford, Toppmeyer, Deborah, Carey, Lisa Anne, Partridge, Ann H, Pierga, Jean-Yves, Fehm, Tanja, Vidal-Martínez, José, Mavroudis, Dimitrios, Garcia-Saenz, Jose A, Stebbing, Justin, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, Antelo, María Luisa, De Mattos-Arruda, Leticia, Generali, Daniele, Caldas, Carlos, Munzone, Elisabetta, Dirix, Luc, Delson, Amy L, Burstein, Harold J, Qadir, Misbah, Ma, Cynthia, Scott, Janet H, Bidard, François-Clément, Park, John W, and Rugo, Hope S

Subjects
Cancer, Prevention, Breast Cancer, Clinical Research, Breast Neoplasms, Female, Humans, Neoplastic Cells, Circulating, Prognosis, Progression-Free Survival, Proportional Hazards Models, Reproducibility of Results, Retrospective Studies, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundWe examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.MethodsSerial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.ResultsLatent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.ConclusionsWe identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.

Published
2021

8. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer

Author

Van Baelen, Karen, Nguyen, Ha-Linh, Hamy-Petit, Anne-Sophie, Richard, François, Karsten, Maria Margarete, Nader Marta, Guilherme, Vermeulen, Peter, Toussaint, Aullene, Reyal, Fabien, Vincent-Salomon, Anne, Dirix, Luc, Dordevic, Adam David, de Azambuja, Evandro, Larsimont, Denis, Amato, Ottavia, Maetens, Marion, De Schepper, Maxim, Geukens, Tatjana, Han, Sileny N., Baert, Thaïs, Punie, Kevin, Wildiers, Hans, Smeets, Ann, Nevelsteen, Ines, Floris, Giuseppe, Biganzoli, Elia, Neven, Patrick, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

9. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights

Author

Latacz, Emily, Höppener, Diederik, Bohlok, Ali, Leduc, Sophia, Tabariès, Sébastien, Fernández Moro, Carlos, Lugassy, Claire, Nyström, Hanna, Bozóky, Béla, Floris, Giuseppe, Geyer, Natalie, Brodt, Pnina, Llado, Laura, Van Mileghem, Laura, De Schepper, Maxim, Majeed, Ali W., Lazaris, Anthoula, Dirix, Piet, Zhang, Qianni, Petrillo, Stéphanie K., Vankerckhove, Sophie, Joye, Ines, Meyer, Yannick, Gregorieff, Alexander, Roig, Nuria Ruiz, Vidal-Vanaclocha, Fernando, Denis, Larsimont, Oliveira, Rui Caetano, Metrakos, Peter, Grünhagen, Dirk J., Nagtegaal, Iris D., Mollevi, David G., Jarnagin, William R., D’Angelica, Michael I, Reynolds, Andrew R., Doukas, Michail, Desmedt, Christine, Dirix, Luc, Donckier, Vincent, Siegel, Peter M., Barnhill, Raymond, Gerling, Marco, Verhoef, Cornelis, and Vermeulen, Peter B.

Published
2022
Full Text
View/download PDF

14. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC

Author

Rypens, Charlotte, Bertucci, François, Finetti, Pascal, Robertson, Fredika, Fernandez, Sandra V., Ueno, Naoto, Woodward, Wendy A., Van Golen, Kenneth, Vermeulen, Peter, Dirix, Luc, Viens, Patrice, Birnbaum, Daniel, Devi, Gayathri R., Cristofanilli, Massimo, and Van Laere, Steven

Published
2022
Full Text
View/download PDF

16. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Parnis, Francis, Joshua, Anthony M., Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Gurney, Howard, Ferguson, Thomas, Van Bruwaene, Siska, Luyten, Daisy, Schatteman, Peter, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Seront, Emmanuel, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Pinczowski, Hélio, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Fizazi, Karim, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Eymard, Jean-Christophe, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Leibowitz-Amit, Raya, Mermershtain, Wilmosh, Rouvinov, Keren, Peer, Avivit, Kovel, Svetlana, Sella, Avishay, Lolkema, Martijn P., van den Eertwegh, Alfonsus J.M., Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Kim, Choung-Soo, Choi, Young-Deuk, Chung, Byung-Ha, Gafanov, Rustem A., Kopyltsov, Evgeniy, Usynin, Evgeny A., Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Estellés, David Lorente, Sarrió, Regina Gironés, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Ståhl, Olof, Chiang, Po-Hui, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Wu, Hsi-Chin, Lu, Yu-Chuan, Attard, Gerhardt, Khoo, Vincent, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Sieber, Paul R., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Flaig, Thomas W., Emamekhoo, Hamid, Pinski, Jacek K., Kalebasty, Arash Rezazadeh, Maly, Joseph J., Moon, Helen, Smith, Matthew R, Scher, Howard I, Lara, Primo N, Jr, Yu, Evan Y, George, Daniel J, Chi, Kim N, Danila, Daniel C, Mason, Gary E, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, and Lopez-Gitlitz, Angela

Published
2022
Full Text
View/download PDF

18. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

Necchi, Andrea, Loriot, Yohann, Park, Se Hoon, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Duran, Ignacio, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, Zakharia, Yousef, Siefker-Radtke, Arlene O, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Tagawa, Scott T, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, and O'Hagan, Anne

Published
2022
Full Text
View/download PDF

19. Pathway-based subnetworks enable cross-disease biomarker discovery.

Author

Haider, Syed, Yao, Cindy Q, Sabine, Vicky S, Grzadkowski, Michal, Stimper, Vincent, Starmans, Maud HW, Wang, Jianxin, Nguyen, Francis, Moon, Nathalie C, Lin, Xihui, Drake, Camilla, Crozier, Cheryl A, Brookes, Cassandra L, van de Velde, Cornelis JH, Hasenburg, Annette, Kieback, Dirk G, Markopoulos, Christos J, Dirix, Luc Y, Seynaeve, Caroline, Rea, Daniel W, Kasprzyk, Arek, Lambin, Philippe, Lio', Pietro, Bartlett, John MS, and Boutros, Paul C

Subjects
Humans, Neoplasms, Treatment Outcome, Signal Transduction, Cell Proliferation, Algorithms, Benchmarking, Metabolic Networks and Pathways, Biomarkers, Tumor, Biotechnology, Genetics, 4.1 Discovery and preclinical testing of markers and technologies, Biomarkers, Tumor
Abstract

Biomarkers lie at the heart of precision medicine. Surprisingly, while rapid genomic profiling is becoming ubiquitous, the development of biomarkers usually involves the application of bespoke techniques that cannot be directly applied to other datasets. There is an urgent need for a systematic methodology to create biologically-interpretable molecular models that robustly predict key phenotypes. Here we present SIMMS (Subnetwork Integration for Multi-Modal Signatures): an algorithm that fragments pathways into functional modules and uses these to predict phenotypes. We apply SIMMS to multiple data types across five diseases, and in each it reproducibly identifies known and novel subtypes, and makes superior predictions to the best bespoke approaches. To demonstrate its ability on a new dataset, we profile 33 genes/nodes of the PI3K pathway in 1734 FFPE breast tumors and create a four-subnetwork prediction model. This model out-performs a clinically-validated molecular test in an independent cohort of 1742 patients. SIMMS is generic and enables systematic data integration for robust biomarker discovery.

Published
2018

20. Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial

Author

Bartlett, John M.S., primary, Xu, Keying, primary, Wong, Jenna, primary, Pond, Gregory, primary, Zhang, Yi, primary, Spears, Melanie, primary, Salunga, Ranelle, primary, Mallon, Elizabeth, primary, Taylor, Karen J., primary, Hasenburg, Annette, primary, Markopoulos, Christos, primary, Dirix, Luc, primary, van de Velde, Cornelis J.H., primary, Rea, Daniel, primary, Schnabel, Catherine A., primary, Treuner, Kai, primary, and Bayani, Jane, primary

Published
2024
Full Text
View/download PDF

23. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Author

Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, investigators, LOTUS, Lee, Keun Seok, Wang, Hwei-Chung, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, and Seigel, Leonard

Subjects
Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Confidence Intervals, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Paclitaxel, Patient Selection, Placebos, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins c-akt, Risk Assessment, Survival Analysis, Treatment Outcome, Triple Negative Breast Neoplasms, LOTUS investigators, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThe oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer.MethodsIn this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium. Enrolled patients were randomly assigned (1:1) to receive intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity. Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour PTEN status. The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochemistry) population. This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).FindingsBetween Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62). Median follow-up was 10·4 months (IQR 6·5-14·1) in the ipatasertib group and 10·2 months (6·0-13·6) in the placebo group. Median progression-free survival in the intention-to-treat population was 6·2 months (95% CI 3·8-9·0) with ipatasertib versus 4·9 months (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumours, median progression-free survival was 6·2 months (95% CI 3·6-9·1) with ipatasertib versus 3·7 months (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18). The most common grade 3 or worse adverse events were diarrhoea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]). No colitis, grade 4 diarrhoea, or treatment-related deaths were reported with ipatasertib. One treatment-related death occurred in the placebo group. Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.InterpretationProgression-free survival was longer in patients who received ipatasertib than in those who received placebo. To our knowledge, these are the first results supporting AKT-targeted therapy for triple-negative breast cancer. Ipatasertib warrants further investigation for the treatment of triple-negative breast cancer.FundingF Hoffmann-La Roche.

Published
2017

24. Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

Author

Bayani, Jane, Yao, Cindy Q, Quintayo, Mary Anne, Yan, Fu, Haider, Syed, D’Costa, Alister, Brookes, Cassandra L, van de Velde, Cornelis JH, Hasenburg, Annette, Kieback, Dirk G, Markopoulos, Christos, Dirix, Luc, Seynaeve, Caroline, Rea, Daniel, Boutros, Paul C, and Bartlett, John MS

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Clinical Research, Patient Safety, Genetics, Breast Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Clinical sciences, Oncology and carcinogenesis, Epidemiology
Abstract

Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53-7.22, p = 7.51 × 10-19). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10-28). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies.

Published
2017

26. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer:Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, Armstrong, Anne, Cuypere, Eveline, Dalenc, Florence, Dirix, Luc, Chan, Steve, Marme, Frederik, Schröder, Carolina P., Huober, Jens, Duhoux, Francois P., Vuylsteke, Peter, Jager, Agnes, Brain, Etienne, Kuemmel, Sherko, Pápai, Zsuzsanna, der Houven van Oordt, Catharina Willemien Menke Van, Perjesi, Luca, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic, Wildiers, Hans, Armstrong, Anne, Cuypere, Eveline, Dalenc, Florence, Dirix, Luc, Chan, Steve, Marme, Frederik, Schröder, Carolina P., Huober, Jens, Duhoux, Francois P., Vuylsteke, Peter, Jager, Agnes, Brain, Etienne, Kuemmel, Sherko, Pápai, Zsuzsanna, der Houven van Oordt, Catharina Willemien Menke Van, Perjesi, Luca, Mueller, Christian, Brignone, Chrystelle, and Triebel, Frederic

Abstract

Purpose: Eftilagimod alpha (efti), a soluble lymphocyte activation gene (LAG-3) protein and MHC class II agonist, enhances innate and adaptive immunity. Active Immunotherapy PAClitaxel (AIPAC) evaluated safety and efficacy of efti plus paclitaxel in patients with predominantly endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer (ET-resistant HR+ HER2– MBC). Patients and Methods: Women with HR+ HER2– MBC were randomized 1:1 to weekly intravenous paclitaxel (80 mg/m2) and subcutaneous efti (30 mg) or placebo every 2 weeks for six 4-week cycles, then monthly subcutaneous efti (30 mg) or placebo maintenance. Primary endpoint was progression-free survival (PFS) by blinded independent central review. Secondary endpoints included overall survival (OS), safety/tolerability, pharmacokinetics/pharmacodynamics, and quality of life. Exploratory endpoints included cellular biomarkers. Results: 114 patients received efti and 112 patients received placebo. Median age was 60 years (91.6% visceral disease, 84.1% ET-resistant, 44.2% with previous CDK4/6 inhibitor treatment). Median PFS at 7.3 months was similar for efti and placebo. Median OS was not significantly improved for efti (20.4 vs. 17.5 months; HR, 0.88; P = 0.197) but became significant for predefined exploratory subgroups. EORTC QLQC30-B23 global health status was sustained for efti but deteriorated for placebo. Efti increased absolute lymphocyte, monocyte and secondary target cell (CD4, CD8) counts, plasma IFNg and CXCL10 levels. Conclusions: Although the primary endpoint, PFS, was not met, AIPAC confirmed expected pharmacodynamic effects and demonstrated excellent safety profile for efti. OS was not significantly improved globally (2.9-month difference), but was significantly improved in exploratory biomarker subgroups, warranting further studies to clarify efti’s role in patients with ET-resistant HER2– MBC.

Published
2024

28. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Author

Vergote, Ignace, Van Nieuwenhuysen, Els, De Waele, Stefanie, Vulsteke, Christof, Lamot, Caroline, Van den Bulck, Heidi, Claes, Nele, Graas, Marie-Pascale, Debrock, Guy, Spoormans, Isabelle, Vuylsteke, Peter, Honhon, Brigitte, Verhoeven, Didier, De Maeseneer, Daan, Dirix, Luc, Mebis, Jeroen, Vroman, Philippe, Denys, Hannelore, Martinez Mena, Corina, Pelgrims, Gino, Van Steenberghe, Mona, van Gorp, Toon, and Gennigens, Christine

Published
2022
Full Text
View/download PDF

29. Figure S6 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

30. Supplementary Data 1 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

31. Data from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Author

Wildiers, Hans, primary, Armstrong, Anne, primary, Cuypere, Eveline, primary, Dalenc, Florence, primary, Dirix, Luc, primary, Chan, Steve, primary, Marme, Frederik, primary, Schröder, Carolina P., primary, Huober, Jens, primary, Duhoux, Francois P., primary, Vuylsteke, Peter, primary, Jager, Agnes, primary, Brain, Etienne, primary, Kuemmel, Sherko, primary, Pápai, Zsuzsanna, primary, Menke-van der Houven van Oordt, Catharina Willemien, primary, Perjesi, Luca, primary, Mueller, Christian, primary, Brignone, Chrystelle, primary, and Triebel, Frederic, primary

Published
2024
Full Text
View/download PDF

32. Data from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

33. Supplementary Figure 12 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

34. TABLE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

35. FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

36. Supplementary Figure 6 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

37. FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

38. Supplementary Figure 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

39. FIGURE 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

40. Supplementary Figure 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

41. Supplementary Table 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

42. FIGURE 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

43. Supplementary Table 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

44. Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

45. Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

46. Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

47. Supplementary Table 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

48. Supplementary Figure 7 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

49. Supplementary Figure 8 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

50. FIGURE 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy

Author

De Schepper, Maxim, primary, Nguyen, Ha-Linh, primary, Richard, François, primary, Rosias, Louise, primary, Lerebours, Florence, primary, Vion, Roman, primary, Clatot, Florian, primary, Berghian, Anca, primary, Maetens, Marion, primary, Leduc, Sophia, primary, Isnaldi, Edoardo, primary, Molinelli, Chiara, primary, Lambertini, Matteo, primary, Grillo, Federica, primary, Zoppoli, Gabriele, primary, Dirix, Luc, primary, Punie, Kevin, primary, Wildiers, Hans, primary, Smeets, Ann, primary, Nevelsteen, Ines, primary, Neven, Patrick, primary, Vincent-Salomon, Anne, primary, Larsimont, Denis, primary, Duhem, Caroline, primary, Viens, Patrice, primary, Bertucci, François, primary, Biganzoli, Elia, primary, Vermeulen, Peter, primary, Floris, Giuseppe, primary, and Desmedt, Christine, primary

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results